As Elvis often said, "It's now or never."With the acquisition of...

As Elvis often said, "It's now or never."

With the acquisition of Tacere and now the appointment of Synteract the die is cast for the advancement of TT-034. This is a bold move after the recent progress made by others in the HCV field and Somagenics decision to "wait and see" before advancing their sshnra treatment into the clinic.

Even if we are successful with the trial the attractiveness of the deal may not be there to entice big pharma to buy into the program. This could mean that BLT will be left to go all the way with the commercialization of the product; a move that would further define BLT's long term future as this would make us a true pharma with R&D, manufacturing and distribution.

So, from my perspective, the entire future of the company now rests on management getting this decision right - but that is what we pay them for.